Alluvi, known as BI 4744, presents a significant breakthrough in weight management care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling efficacy in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/